Physician profile
Jose E Pagan
NPI 1578545901
$15,945.50
in general payments reported to CMS, 2019-2025
32 companies · $2,289 in 2025
The $2,289 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,807 · 2020: $2,607 · 2021: $2,790 · 2022: $1,880 · 2023: $2,020 · 2024: $2,553 · 2025: $2,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,835 · Education: $27.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,834.69 |
| Education | $27.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,209.17 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $2,176.03 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,419.78 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $1,290.65 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $1,193.23 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $1,040.71 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $987.31 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $805.02 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Abbvie INC. | $701.42 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $617.04 | 2019-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $572.27 | 2021-2025 | Qelbree, Qelbree |
| Allergan, INC. | $557.11 | 2019-2020 | |
| Eisai INC. | $429.19 | 2020-2021 | |
| Axsome Therapeutics, INC. | $258.68 | 2023-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $232.72 | 2023-2024 | Quviviq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $221.45 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $186.58 | 2019-2025 | Spravato, Invega Sustenna |
| Tris Pharma INC | $184.21 | 2023-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $153.89 | 2024-2025 | Cobenfy |
| Corium, LLC | $140.47 | 2023-2025 | Azstarys |
| Indivior INC. | $122.92 | 2020-2021 | |
| Stryker Corporation | $113.23 | 2022-2024 | Mako |
| Shire North American Group INC | $78.31 | 2019 | |
| Merck Sharp & Dohme LLC | $58.23 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $53.37 | 2019-2020 | |
| Neuronetics, INC. | $28.77 | 2020-2023 | Neurostar Tms Therapy System |
| Bausch Health US, LLC | $25.66 | 2021 | |
| Ironshore Pharmaceuticals INC. | $23.07 | 2019 | |
| Azurity Pharmaceuticals, INC. | $19.88 | 2022 | |
| Sage Therapeutics, LLC | $19.86 | 2024 | |
| Almatica Pharma LLC | $13.91 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Pagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.